Bayer Net Long-Term Debt 2010-2024 | BAYRY

Bayer annual/quarterly net long-term debt history and growth rate from 2010 to 2024. Net long-term debt can be defined as the net amount of long term debt issued and repaid. This field is either calculated as the sum of the long term debt fields or used if a company does not report debt issued and repaid separately
  • Bayer net long-term debt for the quarter ending December 31, 2024 was $-5.430B, a 254.23% decline year-over-year.
  • Bayer net long-term debt for the twelve months ending December 31, 2024 was $-7.461B, a 145.49% decline year-over-year.
  • Bayer annual net long-term debt for 2024 was $-5.43B, a 254.23% decline from 2023.
  • Bayer annual net long-term debt for 2023 was $3.521B, a 443.08% decline from 2022.
  • Bayer annual net long-term debt for 2022 was $-1.026B, a 64.63% decline from 2021.
Bayer Annual Net Long-Term Debt
(Millions of US $)
2024 $-5,430
2023 $3,521
2022 $-1,026
2021 $-2,901
2020 $5,103
2019 $-4,812
2018 $21,044
2017 $-2,802
2016 $-808
2015 $-3,252
2014 $15,736
2013 $-822
2012 $-2,501
2011 $N/A
2010 $N/A
2009 $N/A
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $28.451B $50.438B
Bayer AG is a life science company with core competencies in the areas of health care and agriculture. With the company's focus completely on the Life Science businesses, a new organizational structure was introduced effective Jan 1, 2016. Bayer Group now comprise exclusively of the Life Science businesses. The company started reporting in three segments ' Pharmaceuticals, Consumer Health and Crop Science ' from the third quarter of 2019. Both Animal Health and Currenta were reported as discontinued operations in the quarter. The company acquired U.S. seed giant Monsanto in June, 2018. With the acquisition, Bayer now has the strongest portfolio of seed and crop protection products for a wide range of crops and indications, the best research and development platform and the leading digital farming business.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $708.072B 54.30
Johnson & Johnson (JNJ) United States $373.904B 15.46
AbbVie (ABBV) United States $330.300B 18.21
Roche Holding AG (RHHBY) Switzerland $259.454B 0.00
Novartis AG (NVS) Switzerland $246.520B 14.08
Merck (MRK) United States $191.466B 9.79
Pfizer (PFE) United States $133.379B 7.31
Sanofi (SNY) France $120.637B 11.88
Innoviva (INVA) United States $1.264B 13.25
Novo Nordisk (NVO) Denmark $0.000B 21.55